Outpatient treatment with epirubicin and oral etoposide in patients with small-cell lung cancer.

To assess the efficacy and toxicity of an outpatient combination chemotherapy in small-cell lung cancer (SCLC), we treated 70 consecutive patients with epirubicin 80 mg m(-2) i.v. on day 1 and etoposide 200 mg o.d. p.o. on days 1-4 (EE) at 3-weekly intervals. The median age of patients was 64 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Gogas, H., Lofts, F. J., Evans, T. R., Millard, F. J., Wilson, R., Mansi, J. L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228002/
https://www.ncbi.nlm.nih.gov/pubmed/9303364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228002/
https://www.ncbi.nlm.nih.gov/pubmed/9303364

Ejemplares similares